Gain Therapeutics, Inc. (GANX) Reports In-Line Q3 EPS

Gain Therapeutics, Inc. (NASDAQ: GANX) reported Q3 EPS of ($0.15), in-line with the analyst estimate of ($0.15).

For earnings history and earnings-related data on Gain Therapeutics, Inc. (GANX) click here.

You May Also Be Interested In

• VNET Group (VNET) Misses Q2 EPS by 164c
• H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)
• H.C. Wainwright Reiterates Buy Rating on Jasper Therapeutics (JSPR)